Porton(SZ:300363)2023-02-04 17:34Group 1: Market Trends and Production Capacity - Overseas CDMO companies are experiencing price increases due to inflation, but strategies vary by business segment and market [1] - The capacity utilization rates of the three factories differ slightly, with the Jiangxi factory maintaining a high utilization rate, while the Changshou and Hubei factories are gradually filling their capacities [1] - The company’s formulation factory projects are currently all from domestic clients [2] Group 2: Project Developments and Future Plans - The Slovenia project, announced in 2022, is in the early engineering design phase and is expected to be operational by Q3 2024, serving as a research and production base in Europe [2] - The company is involved in the entire ADC service cycle due to its capabilities in small molecules [2] - The GCT business pipeline is primarily in the preclinical stage, with two client projects successfully applying for IND last year [3] Group 3: Business Strategy and Talent Expansion - The company’s new business layout is driven by both market demand and proactive planning [2] - In 2022, the company expanded its workforce by approximately 1,700 employees, with 2023 recruitment focusing on new business and capabilities [3] - The company plans to consider specific financing plans based on business needs [3] Group 4: Financial and Capital Expenditure - The company’s capital expenditure plan for 2022 was approximately 1.7 billion, with actual execution within this range [3] - The number of commercialized API projects remains in single digits, but the number of PV projects has reached several dozen over the past two years, with more commercial projects expected to materialize after 2024 [3]